Drugs / 161Tb-PSMA-I&T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07621692 | Jan 2026 → Dec 2030 expected | prostate carcinoma | National Taiwan University Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 161Tb-PSMA-I&T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07621692 ↗ |
| Route | Intravenous | “slow intravenous administration” NCT07621692 ↗ |